Insider Chart Past 6 Months
Technical Chart
Filings by transaction date
-
Apr 17, 2024 (filed on Apr 19, 2024)Insider Name:Blanchfield PaulOwnership Type:Direct OwnershipSecurities:Common StockNature of Transaction:F - Payment of exercise price or tax liability, exercise or vesting of a security under Rule 16b-3# or value acquired/disposed of:-455Price:$61.48
-
Apr 15, 2024 (filed on Apr 17, 2024)Insider Name:Sabens AndreaOwnership Type:Direct OwnershipSecurities:Common StockNature of Transaction:S - Open market or private sale# or value acquired/disposed of:-341Price:$61.24
-
Apr 04, 2024 (filed on Apr 04, 2024)Insider Name:Morgan Amanda MichelleOwnership Type:Direct OwnershipSecurities:Stock Option (Right to Buy)Nature of Transaction:Form 3 : Initial Statement of Beneficial Ownership of Securities# or value acquired/disposed of:--Price:--
-
Apr 04, 2024 (filed on Apr 04, 2024)Insider Name:Morgan Amanda MichelleOwnership Type:Direct OwnershipSecurities:Stock Option (Right to Buy)Nature of Transaction:Form 3 : Initial Statement of Beneficial Ownership of Securities# or value acquired/disposed of:--Price:--
-
Apr 04, 2024 (filed on Apr 04, 2024)Insider Name:Morgan Amanda MichelleOwnership Type:Direct OwnershipSecurities:Common StockNature of Transaction:Form 3 : Initial Statement of Beneficial Ownership of Securities# or value acquired/disposed of:--Price:--
-
Mar 15, 2024 (filed on Mar 19, 2024)Insider Name:Marshall Robert J. Jr.Ownership Type:Direct OwnershipSecurities:Common StockNature of Transaction:S - Open market or private sale# or value acquired/disposed of:-20,000Price:$60.00
-
Mar 13, 2024 (filed on Mar 15, 2024)Insider Name:Sabens AndreaOwnership Type:Direct OwnershipSecurities:Common StockNature of Transaction:S - Open market or private sale# or value acquired/disposed of:-341Price:$60.48
-
Mar 07, 2024 (filed on Mar 11, 2024)Insider Name:Blanchfield PaulOwnership Type:Direct OwnershipSecurities:Common StockNature of Transaction:G - Gift# or value acquired/disposed of:-500Price:--
-
Mar 07, 2024 (filed on Mar 11, 2024)Insider Name:Blanchfield PaulOwnership Type:Direct OwnershipSecurities:Common StockNature of Transaction:S - Open market or private sale# or value acquired/disposed of:-18,023Price:$61.96
-
Mar 06, 2024 (filed on Mar 07, 2024)Insider Name:Leno Sam ROwnership Type:Direct OwnershipSecurities:Stock Option (right to buy)Nature of Transaction:M - Exercise or conversion exempt under rule 16b-3# or value acquired/disposed of:-2,045Price:--
Filings by filing date
-
Apr 17, 2024 (filed on Apr 19, 2024)Insider Name:Blanchfield PaulOwnership Type:Direct OwnershipSecurities:Common StockNature of Transaction:F - Payment of exercise price or tax liability, exercise or vesting of a security under Rule 16b-3# or value acquired/disposed of:-455Price:$61.48
-
Apr 15, 2024 (filed on Apr 17, 2024)Insider Name:Sabens AndreaOwnership Type:Direct OwnershipSecurities:Common StockNature of Transaction:S - Open market or private sale# or value acquired/disposed of:-341Price:$61.24
-
Apr 04, 2024 (filed on Apr 04, 2024)Insider Name:Morgan Amanda MichelleOwnership Type:Direct OwnershipSecurities:Stock Option (Right to Buy)Nature of Transaction:Form 3 : Initial Statement of Beneficial Ownership of Securities# or value acquired/disposed of:--Price:--
-
Apr 04, 2024 (filed on Apr 04, 2024)Insider Name:Morgan Amanda MichelleOwnership Type:Direct OwnershipSecurities:Stock Option (Right to Buy)Nature of Transaction:Form 3 : Initial Statement of Beneficial Ownership of Securities# or value acquired/disposed of:--Price:--
-
Apr 04, 2024 (filed on Apr 04, 2024)Insider Name:Morgan Amanda MichelleOwnership Type:Direct OwnershipSecurities:Common StockNature of Transaction:Form 3 : Initial Statement of Beneficial Ownership of Securities# or value acquired/disposed of:--Price:--
-
Mar 15, 2024 (filed on Mar 19, 2024)Insider Name:Marshall Robert J. Jr.Ownership Type:Direct OwnershipSecurities:Common StockNature of Transaction:S - Open market or private sale# or value acquired/disposed of:-20,000Price:$60.00
-
Mar 13, 2024 (filed on Mar 15, 2024)Insider Name:Sabens AndreaOwnership Type:Direct OwnershipSecurities:Common StockNature of Transaction:S - Open market or private sale# or value acquired/disposed of:-341Price:$60.48
-
Mar 07, 2024 (filed on Mar 11, 2024)Insider Name:Blanchfield PaulOwnership Type:Direct OwnershipSecurities:Common StockNature of Transaction:G - Gift# or value acquired/disposed of:-500Price:--
-
Mar 07, 2024 (filed on Mar 11, 2024)Insider Name:Blanchfield PaulOwnership Type:Direct OwnershipSecurities:Common StockNature of Transaction:S - Open market or private sale# or value acquired/disposed of:-18,023Price:$61.96
-
Mar 06, 2024 (filed on Mar 07, 2024)Insider Name:Leno Sam ROwnership Type:Direct OwnershipSecurities:Stock Option (right to buy)Nature of Transaction:M - Exercise or conversion exempt under rule 16b-3# or value acquired/disposed of:-2,045Price:--
News
Biz Brief
Sector: Healthcare | Industry: Medical Equipment, Supplies & Distribution |
See Regulatory Filings on SEC |
Company Contact | |
Address: | 331 Treble Cove Rd NORTH BILLERICA MA 01862 |
Tel: | 1-978-6718842 |
Website: | https://www.lantheus.com |
IR: | See website |
Key People | ||
Mary Anne Heino Chairman of the Board | Paul M. Blanchfield President | Brian A. Markison Chief Executive Officer, Director |
Robert J. Marshall Chief Financial Officer, Treasurer | Daniel M. Niedzwiecki Chief Administrative Officer, General Counsel, Corporate Secretary | Etienne Montagut Chief Business Officer |
Amanda Morgan Chief Commercial Officer | Jean-Claude Provost Chief Medical Officer |
Business Overview |
Lantheus Holdings, Inc. is a radiopharmaceutical-focused company. The Company is engaged in delivering science to enable clinicians to find, fight and follow disease to deliver patient outcomes. The Company classifies its products in three categories: Radiopharmaceutical Oncology, Precision Diagnostics, and Strategic Partnerships. Its Radiopharmaceutical Oncology diagnostics and therapeutic candidates help healthcare professionals (HCPs) find, fight, and follow cancer, with a focus in prostate cancer. Its Precision Diagnostic products assist HCPs to find and follow diseases, with a focus in cardiology. Its Strategic Partnerships focus on enabling precision medicine through the use of biomarkers, digital solutions and pharma solutions platforms. Its commercial products include PYLARIFY, DEFINITY, TechneLite, NEUROLITE, Xenon-133, CARDIOLITE, RELISTOR, Automated Bone Scan Index, and others. Its commercial products are used by cardiologists, internal medicine physicians, and others. |
Financial Overview |
For the fiscal year ended 31 December 2023, Lantheus Holdings Inc revenues increased 39% to $1.3B. Net income increased from $28.1M to $326.7M. Revenues reflect PYLARIFY segment increase of 61% to $851.3M, DEFINITY segment increase of 14% to $279.8M. Net income benefited from Other Research and Development decrease of 77% to $70.6M (expense), Other General and administrative decrease of 23% to $91.2M (expense). |
Employees: | 834 as of Dec 31, 2023 |
Reporting Currency: | U.S. Dollars |
Enterprise value: | $4,319M as of Dec 31, 2023 |
Annual revenue (TTM): | $1,296M as of Dec 31, 2023 |
EBITDA (TTM): | $556.69M as of Dec 31, 2023 |
Net annual income (TTM): | $326.66M as of Dec 31, 2023 |
Free cash flow (TTM): | $213.36M as of Dec 31, 2023 |
Net Debt Last Fiscal Year: | N/A |
Shares outstanding: | 68,551,404 as of Mar 1, 2024 |
Index Membership: | S&P 400 Mid Cap |
TTM: Trailing Twelve Months EBITDA: Earnings Before Interest, Taxes, Depreciation, & Amortization |